371References
Acharya CR, Hsu DS, Anders CK, et al. Gene expression signatures, clinicopathological features,
and individualized therapy in breast cancer. JAMA. 2008;299:1574–87.
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
has signifi cant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol.
2013;31:88–94.
Agadjanian H, Ma J, Rentsendorj A, et al. Tumor detection and elimination by a targeted gallium
corrole. Proc Natl Acad Sci U S A. 2009;106:6105–10.
Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells
unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8:158–66.
Anderson AR, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolu-
tion driven by selective pressure from the microenvironment. Cell. 2006;127:905–15.
Ando M, Hasegawa Y, Ando Y. Pharmacogenetics of irinotecan: a promoter polymorphism of
UGT1A1 gene and severe adverse reactions to irinotecan. Invest New Drugs. 2005;23:
539–45.
Andrechek ER, Cardiff RD, Chang JT, et al. Genetic heterogeneity of Myc-induced mammary
tumors refl ecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A.
2009;106:16387–92.
Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging
for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
J Nucl Med. 2004;45:357–65.
Bailey VJ, Easwaran H, Zhang Y, et al. MS-qFRET: a quantum dot-based method for analysis of
DNA methylation. Genome Res. 2009;19:1455–61.
Beier D, Röhrl S, Pillai DR, et al. Temozolomide preferentially depletes cancer stem cells in glio-
blastoma. Cancer Res. 2008;68:5706–15.
Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgi-
cal resection and have a survival benefi t associated with maximal surgical resection. Neuro
Oncol. 2014;16:81–91.
Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic
syndromes. N Engl J Med. 2011;364:2496–506.
Benavides LC, Gates JD, Carmichael MG, et al. The impact of HER2/neu expression level on
response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study
I-01 and I-02. Clin Cancer Res. 2009;15:2895–904.
Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response.
J Nucl Med. 2009;50:88–99.
Berd D. M-Vax: an autologous, hapten-modifi ed vaccine for human cancer. Expert Rev Vaccines.
2004;3:521–7.
Bhagwat NR, Roginskaya VY, Acquafondata MB, et al. Immunodetection of DNA repair endo-
nuclease ERCC1-XPF in human tissue. Cancer Res. 2009;69:6831–8.
Bordeaux JM, Cheng H, Welsh AW, et al. Quantitative in situ measurement of estrogen receptor
mRNA predicts response to tamoxifen. PLoS One. 2012;7:e36559.
Boucek JA, Turner JH. Personalized dosimetry of (131)i-rituximab radioimmunotherapy of non-
Hodgkin lymphoma defi ned by pharmacokinetics in bone marrow and blood. Cancer Biother
Radiopharm. 2014;29:18–25.
Bosco EE, Wang Y, Xu H, et al. The retinoblastoma tumor suppressor modifi es the therapeutic
response of breast cancer. J Clin Invest. 2007;117:218–28.
Boyer J, Allen WL, McLean EG, et al. Pharmacogenomic identifi cation of novel determinants of
response to chemotherapy in colon cancer. Cancer Res. 2006;66:2765–77.
Bredel M, Scholtens DM, Harsh GR, et al. A network model of a cooperative genetic landscape in
brain tumors. JAMA. 2009;302:261–75.
Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute
lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426–35.
References